ProfileGDS5678 / 1455925_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 71% 71% 71% 67% 67% 71% 69% 71% 71% 72% 76% 70% 71% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.4499771
GSM967853U87-EV human glioblastoma xenograft - Control 24.4387371
GSM967854U87-EV human glioblastoma xenograft - Control 34.4450871
GSM967855U87-EV human glioblastoma xenograft - Control 44.087967
GSM967856U87-EV human glioblastoma xenograft - Control 54.0133867
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.4608271
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.2696369
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.427171
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.4482871
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.5553872
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.1062276
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.3754370
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.4656571
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.4338271